Home > For Media

New York Hospital Queens Nationally Recognized Diabetes Expert Says Efforts to Reduce Heart Attacks in Diabetic Patients are on the Right Track

FOR IMMEDIATE RELEASE
CONTACTS:
Cynthia Bacon (718) 670-2515
David Levine (212) 772-9447

Comments by One of the Principal Investigators of the ACCORD Trial

Flushing, N.Y March 17, 2010 – New York Hospital Queens (NYHQ) was one of the investigative sites for the ACCORD  trial (Action to Control Cardiovascular Risk in Diabetes), which looked at the effectiveness of an aggressive treatment regimen to prevent heart attacks and strokes in patients with Type 2  diabetes. The results were presented at the American College of Cardiology meeting this past weekend and published online in The New England Journal of Medicine.

According to government figures, there are an estimated 24 million Americans and 730,000 New Yorkers with Type 2 diabetes.  “Because adults with diabetes are two to four times more likely to have heart disease or suffer a stroke than people without diabetes, the federal government has made it a priority to reduce these numbers,” says Daniel Lorber, M.D., F.A.C.P., C.D.E, director of NYHQ’s Division of Endocrinology and Associate Director of the Theresa and Eugene M. Lang Center for Research and Education. Dr. Lorber was a principal investigator for the ACCORD trial. 

The trial began in 1999 and over the years recruited over 10,000 participants including 62 patients from NYHQ who enrolled from January 2001 – October 2005. The investigators found that  aggressively lowering blood pressure below the current recommended  levels or adding a fibrate drug that lowers triglycerides and raises HDL (the good cholesterol) with a statin drug (which lowers LDL or the bad cholesterol) did not achieve the outcomes that heart and diabetes experts had hoped for in most patients. The drug did decrease cardiovascular events in the patient subjects with the lowest HDL and highest triglycerides.

Dr. Lorber says the results show that despite these findings the approach that the medical community has been taking in diabetes is the correct one. “Controlling cholesterol, especially LDL cholesterol, is key in preventing heart attacks and strokes. Having good blood pressure and glucose control is also important. The ACCORD study showed that sometimes doing more does not translate to doing better and that aggressive treatment is not the answer for every patient.”

The ACCORD trial is one of three national trials sponsored by the National Institutes of Health (NIH) for which NYHQ has served as an investigational site. The Center’s director, Phyllis August, M.D., M.P.H., was a principal investigator (along with Dr. Lorber) and on the writing committee for BARI 2D, short for the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes study. This study found that there was no significant advantage of prompt revascularization over intensive medical therapy on mortality and major cardiovascular events in patients with Type 2 diabetes and stable coronary artery disease. 

The Center is currently involved in a new NIH study, known as TINSAL-T2D, to determine whether aspirin relatives, called salicylates, represent a new treatment  option  for  patients with Type 2 diabetes. The goal of this nationwide research study is to determine the effectiveness of the drug salsalate on this population. NYHQ is actively looking for volunteers for the study who have Type 2 diabetes and are between the ages of 18 to 75. People with diabetes who meet the criteria and are interested in taking part in this study should call (718) 670-2914 for further information.

Research at NYHQ is coordinated by the Lang Center for Research and Education which was established in 2001. The goal of the Center is to create new knowledge by conducting cutting-edge clinical research and to integrate excellent clinical care with research and education. Generous funding by the Lang family has helped to make possible the over 120 research studies currently in progress at NYHQ.

New York Hospital Queens is a member of the NewYork-Presbyterian Healthcare System and an affiliate of the Weill Medical College of Cornell University.

###

Note to Editors: Dr. Lorber is available for interviews on diabetes and the ACCORD and TINSAL trials. His special interests include diabetes and all its health care and social aspects. He has held numerous committee positions for a variety of state and national organizations focused on diabetes including the New York Diabetes Association and the American Diabetes Association.  In 2009, the American Diabetes Association awarded Dr. Lorber its “Outstanding Physician Clinician Award” for his years of dedication and research.

 

 

 
Connect Healthcare Panacea CMS Solutions
Site Map | Contact Us | Privacy Policy | Term of Use
Copyright © 2014 New York Hospital Queens
56-45 Main Street, Flushing, NY 11355